News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UCB Group’s Cimzia Cuts Arthritis Joint Damage at 16 Weeks
June 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 12 (Reuters) - UCB's drug Cimzia stops structural damage to joints in patients with rheumatoid arthritis as soon as 16 weeks after the start of treatment, according to new data presented on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
Insights
The Brave New World of Radiotherapeutics
April 1, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Rare diseases
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
March 31, 2026
·
2 min read
·
Heather McKenzie
Immunology and inflammation
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
March 31, 2026
·
4 min read
·
Tristan Manalac
